Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.62 |
| ▸ | CNR2 | P34972 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 4/20 | 0.40 |
| ▸ | SKP1 | P63208 | 4/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545472 | 0.91 | CNR1 (0.49) | CNR1CNR2KDM4ESMN1; SMN2LMNA | |
| SCHEMBL14545074 | 0.89 | CNR1 (0.62) | CNR1CNR2KDM4ESMN1; SMN2LMNA | |
| SCHEMBL14545675 | 0.83 | CNR1 (0.70) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14545434 | 0.83 | CNR1 (0.70) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14545360 | 0.83 | CNR1 (0.72) | CNR1CNR2KDM4ECKS1BSKP1 | |
| SCHEMBL14545070 | 0.83 | CNR1 (0.63) | CNR1CNR2KDM4ESMN1; SMN2LMNA | |
| SCHEMBL14545101 | 0.83 | LMNA (0.44) | CNR1CNR2SMN1; SMN2LMNAHTT | |
| SCHEMBL14545354 | 0.83 | CNR1 (0.71) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14545433 | 0.83 | CNR1 (0.71) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14544989 | 0.83 | ALDH1A1 (0.46) | CNR1CNR2KDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885KDM4E 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.